Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics

Main Article Content

Dr Sanjay Kalra
Dr Saptarshi Bhattacharya
Dr Shehla Shaikh


Type 2 diabetes mellitus (T2DM) is a multifactorial disease. Newer facets of its causation, clinical course, complications and therapy are being unraveled regularly. This editorial describes imeglimin, a first-of-class oxidative phosphorylation inhibitor, that has been approved for T2DM in Japan and India.

Article Details

How to Cite
Dr Sanjay Kalra, Dr Saptarshi Bhattacharya, & Dr Shehla Shaikh. (2022). Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics. Indian Journal Of Clinical Practice, 33(5), 8–10. Retrieved from
Guest Editorial

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>